Abic Marketing Ltd, Israel

NSAID. Diclofenac Sodium 50 mg, 100 mg.
SUPPS: 10. 2 supps. at night.
Rheumat. arthr., osteoarthr., low back pain,
other acute musculosk. disord. such as
periarthr., tendin., tenosynov., bursitis,
sprains, strains, dislocation, ankyl.
spondylitis, acute gout. Control of pain/
inflamm. in orthopedic, dental, and other
minor surgery.
S.R. TABS: 20. 1 tab. dly.
Rheum. arthrit., other rheum. conds.
C/I: Hypersens. to the product. Active
gastr./ intest. ulcer, bleeding or perfor.
Active/ history of recur. peptic ulcer/
haemorrhage (>=2 distinct epis. of
proven ulcer./ bleeding). History of GI
bleeding/perfor., relating to prev. NSAID
tmt. Last trimester of pregn. Sev. hepatic
and renal failure. Establ. CHF (NYHA class
II-IV), isch. heart dis., periph. arter. dis.,
cerebrovasc. dis. Pts. in whom aspirin or
other NSAIDs have induc. sympt. of
asthma, acute rhinitis precipit. by
ibuprofen, urticaria, nasal polyps,
angioedema, bronchospasm, other
sympt. of allergic react. (anaphyl. react.
have occur. in such pts). Pts with sev.
heart failure. Tmt of peri-operative pain
in CABG surg.

Opioid. Fentanyl (as citrate) 200, 400, 600, 800, 1200, 1600 mcg/dose.
COMPRESSED TAB. ON HANDLE
(lozenge): 30. Initial: 200 μg. To supply
only 6 x 200 μg and to use all units bef. incr. to higher dose. See lit. Unit to be
sucked, not chewed over 15 mins.
Discont: Grad. downward titrat.
Manage. breakthrough cancer pain in pts
16 and older with maligns. who are
already receiv. and tolerant to opioid ther.
for persist. cancer pain.
C/I: Post-op. pain, opioid non-tol.,
hypersens./intol. to fentanyl, anaphylax.
See lit.

Bisphosphonate. Risedronate Sodium 150 mg.
TABS.:1,2,3,4. Tab wkly. to be swallowed whole and not sucked or chewed in an upright position with glass of plain water, at least 30 mins. bef. first food, other medicine or drink (except water) of the day. Pts should not lie down for 30 mins aft. taking tab.
Tmt. of postmenopaus. osteoporosis. Prevent. of postmenopaus. osteoporosis
C/I:  Hypersens. Hypocalcaem. Preg., lact.
Severe renal impair.(CrCl <30 ml/min).
Inabil. to stand or sit upright for at least 30 min.

Thiazolidinediones. Pioglitazone 15, 30, 45 mg.
TABS.: 15 mg, 30 mg, 45
mg x 28.
Once dly with or w/o food. Initial treat.:
15 mg or 30 mg once dly; may be
increased up to 45 mg once dly. May
be used in combination with insulin.
See lit. Elderly: No dose adjustment is
necessary. Renal impair.ent: No dose
adjustment is necessary in pts. with
impaired renal func. (CLcr > 4 ml/min) Not to be used in dialysed pts. Hepatic
impair.ent: should not be used in pts.
With hepatic impair.ent Paediatric: Not
to be used in children and adolescents
under 18 yrs of age.
As second or third line treatment of type 2
diabetes mellitus: as monotherapy: in
adult patients (particularly overweight
patients) inadequately controlled by diet
and exercise for whom metformin is
inappropriate because of
contraindications or intolerance as dual
oral therapy in combination with
metformin, in adult patients (particularly
overweight patients) with insufficient
glycaemic control despite maximal
tolerated dose of monotherapy with
metformin; with a sulphonylurea, only in
adult patients who show intolerance to
metformin or for whom metformin is
contraindicated, with insufficient
glycaemic control despite maximal
tolerated dose of monotherapy with a
sulphonylurea. As triple oral therapy in
combination with: metformin and a
sulphonylurea, in adult patients
(particularly overweight patients) with
insufficient glycaemic control despite dual
oral therapy.Pioglitazone is also indicated
for combination with insulin in type 2
diabetes mellitus adult patients with
insufficient glycaemic control on insulin
for whom metformin is inappropriate
because of contraindications or
intolerance.After initiation of therapy with
pioglitazone, patients should be reviewed
after 3 to 6 months to assess adequacy of
response to treatment (e.g. reduction in
HbA1c). In patients who fail to show an
adequate response, pioglitazone should
be discontinued. In light of potential risks
with prolonged therapy, prescribers should
confirm at subsequent routine reviews
that the benefit of pioglitazone is
maintained.
C/I: Hypersens. to product; cardiac
failure or history of cardiac failure (NYHA
stages I to IV); hepatic impair.ent;
diabetic ketoacidosis; current bladder
cancer or a history of bladder cancer;
uninvestigated macroscopic haematuria.

α1 Blocker. Alfuzosin HCl 10 mg.
E.R. TABS: 30. 10 mg dly, immed. aft.
even. meal. Swallow whole with fluid.
Not to be crushed, chew. or divid.
Start ther. on day of insert. of urethral
cath. Tmt. 3-4 days, i.e. 2-3 days
during catheterizat. and 1 day follow.
removal.
Tmt. funct. sympts. BPH, espec. if surg.
delayed. Adjuv. tmt. to cathet. in acute
urinary retent. rel. to BPH.
C/I: Known hypersens., postural
hypotens., liver fail., severe kidney fail.,
combinat. with other alpha 1 blockers,
child.